Comparison · NCT03505021-sae
Levosimendan vs Placebo for Levosimendan: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Levosimendan vs Placebo for Levosimendan: serious adverse events. Trial comparisons, record NCT03505021-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03505021-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.273 | 0.227 | 0.324 | wilson | |
| Risk in group 2 | 0.271 | 0.209 | 0.343 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00192 | -0.0834 | 0.082 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.742 | 1.37 | log | |
| Odds ratio, group 1 over group 2 | 1.01 | 0.663 | 1.54 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Levosimendan than on Placebo for Levosimendan | 520 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Levosimendan | Levosimendan 1 mg capsules for oral administration, once to twice a day. The total duration of treatment 48 weeks~Levosimendan: Levosimendan 1 mg capsule for oral administration | 89 | 326 | EG000 |
| Group 2 | Placebo for Levosimendan | Placebo capsule for oral administration, once to twice a day. The total duration of treatment 48 weeks.~Placebo for levosimendan: Placebo capsule for oral administration | 45 | 166 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From signing an informed consent until 25 days from stopping the treatment, up to 51 weeks.
Source ClinicalTrials.gov
Trial
- Title
- Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS
- NCT number
- NCT03505021
- Phases
- PHASE3
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Levosimendan, Placebo for levosimendan
- Lead sponsor
- Orion Corporation, Orion Pharma
- Results first posted
- 2021-08-31
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03505021?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03505021-sae